SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS) today announced that results from its CORE I clinical study, one of two of the company’s pivotal Phase III clinical studies with UCERIS™ (budesonide) in ulcerative colitis, have been published online in the journal Gastroenterology. The article titled, Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients with Mild to Moderate Ulcerative Colitis – Results from the CORE I Study can be found online at www.gastrojournal.org.
